Get the Stockscreener App
2.57
0.78%
0.02
After Hours:
2.56
-0.010
-0.39%
Scpharmaceuticals Inc stock is traded at $2.57, with a volume of 249.63K.
It is up +0.78% in the last 24 hours and down -14.33% over the past month.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
See More
Previous Close:
$2.55
Open:
$2.55
24h Volume:
249.63K
Relative Volume:
0.58
Market Cap:
$129.73M
Revenue:
$17.63M
Net Income/Loss:
$-57.71M
P/E Ratio:
-1.7365
EPS:
-1.48
Net Cash Flow:
$-60.45M
1W Performance:
+27.54%
1M Performance:
-14.33%
6M Performance:
-41.46%
1Y Performance:
-41.86%
1-Day Range:
$2.50
$2.5891
1-Week Range:
$2.00
$2.71
52-Week Range:
$1.94
$5.65
Scpharmaceuticals Inc Stock (SCPH) Company Profile
Name
Scpharmaceuticals Inc
Sector
Industry
Phone
617-517-0730
Address
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
Compare SCPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
2.57 | 129.73M | 17.63M | -57.71M | -60.45M | -1.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | Craig Hallum | Buy |
| Dec-01-22 | Initiated | Cowen | Outperform |
| Oct-21-22 | Resumed | Jefferies | Buy |
| Oct-11-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-02-22 | Initiated | Maxim Group | Buy |
| Sep-09-21 | Initiated | SVB Leerink | Mkt Perform |
| Oct-15-19 | Initiated | H.C. Wainwright | Buy |
| Jan-30-19 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
View All
Scpharmaceuticals Inc Stock (SCPH) Latest News
Corebridge Financial Inc. Raises Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Raymond James Financial Inc. Makes New $318,000 Investment in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
U.S. FDA approves ScPharmaceuticals' heart failure therapy - MarketScreener
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower - simplywall.st
Charles Schwab Investment Management Inc. Acquires 26,964 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Bank of New York Mellon Corp Raises Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
scPharmaceuticals stock hits 52-week low at $2.73 By Investing.com - Investing.com South Africa
scPharmaceuticals stock hits 52-week low at $2.73 - Investing.com India
Maxim Group Cuts scPharmaceuticals (NASDAQ:SCPH) Price Target to $12.00 - Defense World
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Report Preview: Wh - GuruFocus
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025 - MSN
Optimistic Buy Rating for scPharmaceuticals Amid Strong Q4 Results and Promising Developments - TipRanks
Analyst Expectations For scPharmaceuticals's Future - Benzinga
Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating - Marketscreener.com
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: R - GuruFocus
scPharmaceuticals Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com Australia
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com
scPharmaceuticals Inc. SEC 10-K Report - TradingView
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
scPharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
scPharmaceuticals Inc (SCPH) Q4 Earnings: EPS Misses, Revenue Be - GuruFocus
SCPHARMACEUTICALS Earnings Results: $SCPH Reports Quarterly Earnings - Nasdaq
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Earnings Scheduled For March 19, 2025 - Benzinga
SCPHARMACEUTICALS Earnings Preview: Recent $SCPH Insider Trading, Hedge Fund Activity, and More - Nasdaq
ScPharma Eyes New Frontiers For Furoscix - RTTNews
scPharmaceuticals - The Pharma Letter
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 - The Manila Times
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, ... - Post Register
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
Scpharmaceuticals at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rhumbline Advisers - Defense World
scPharmaceuticals (SCPH) to Release Earnings on Wednesday - Armenian Reporter
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD - Yahoo
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target - Investing.com India
Strategic Market Expansion and Strong Sales Foundation Drive Buy Rating for scPharmaceuticals - TipRanks
HC Wainwright Cuts Earnings Estimates for scPharmaceuticals - Defense World
FDA nod for scPharmaceuticals’ Furoscix sNDA - The Pharma Letter
ScPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix -March 06, 2025 at 05:42 pm EST - Marketscreener.com
FDA Approves Expansion for Furosemide Injection to Treat Edema In Patients With CKD - Pharmacy Times
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease - The Manila Times
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the ... - The Bakersfield Californian
FUROSCIX Scores Crucial FDA WinNew CKD Treatment Could Transform Patient Care - StockTitan
SCPH stock touches 52-week low at $3.07 amid market challenges By Investing.com - Investing.com South Africa
SCPH stock touches 52-week low at $3.07 amid market challenges - Investing.com India
FY2029 Earnings Forecast for SCPH Issued By HC Wainwright - Defense World
Scpharmaceuticals Inc Stock (SCPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Scpharmaceuticals Inc Stock (SCPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 10% Owner |
Aug 13 '24 |
Buy |
4.00 |
500,000 |
2,000,000 |
5,806,670 |
| Nokes Rachael | CFO and Treasurer |
Aug 06 '24 |
Option Exercise |
0.00 |
10,445 |
0 |
72,851 |
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):